Bright Minds Biosciences has completed its Phase I first-in-human study of BMB-101 being developed for the treatment of refractory epilepsies, psychosis, addiction, and impulse control disorders. The three-part study assessed the pharmacokinetic (PK), tolerability, safety, and food effect of the 5-HT2C agonist BMB-101 in healthy volunteers.